Abstract
Many studies have found that ruthenium complexes have unique biochemical characteristics and thus inhibit tumor growth or metastasis. Our aim was to report a novel dual-targeting ruthenium candidate 2b with both antitumor and antimetastatic functions that could target tumor sites using both EPR effects and TF/TFR. It was composed of ruthenium-complexed carboline acid and four chloride ions. In vitro, 2b could trigger DNA cleavage and thus block the cell cycle and cause apoptosis by the PARP/ATM pathway. In vivo, 2b could inhibit not only LLC tumor growth but also lung metastasis. We found apoptosis and decrease in CD31 expression in tumor tissue. In addition, we also found that 2b could collect in tumor tissue. Thus, we concluded that 2b could target tumors, inhibit tumor growth and prevent lung metastasis.
Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells
